ABM is an innovative drug discovery and development company focusing on small molecule targeted therapy for the possible treatments of brain cancers including GBM, as well as brain metastasis from melanoma, lung cancer, and breast cancer. It was founded in 2015 by a group of biotech and pharmaceutical industry veterans with more than 20 years of experience in the development of neurological drugs and enterprise management from North America. Since establishment, ABM is building its broad proprietary pipeline internally to construct a brain medicine R&D platform through collaborations with CROs and partners. Our leading program ABM-1310, is highly potent and selective BRAF inhibitor with an excellent cell permeability and brain penetration. The compound was designed to address cancers with BRAFV600 mutation. BRAF mutation happens in about 8% total cancers, such as colorectal cancer, melanoma drug resistance and brain metastasis, and glioma (current drugs are limited by poor brain penetration), as potentially the best-in-class. It was granted the Investigational New Drug (IND) approval in November 2019 in the USA. (Clinical trial information: NCT04190628) More information about ABM’s ongoing ABM-1310 trial is available at www.ClinicalTrials.gov and on the company website at www.abmtx.com. ABM-1310 also got IND approval by NMPA in China in November 2021. ABM-168 is a potent allosteric MEK inhibitor with good cell permeability and BBB penetration. Our approach is to combine ABM-168 with another oncogenic driver inhibitor such as a BRAF inhibitor. The compound received IND approval by FDA in Oct. 2022.
